New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
05:19 EDTRDS.A, WOPEYShell reduces interest in Woodside Petroleum by 156.5M shares
Shell (RDS.A) announced the sale of a total of approximately 156.5M shares in Woodside Petroleum (WOPEY) representing a total estimated value to Shell of around $5B on an after tax basis. The sale, which represents 19% of Woodside's issued share capital, is through an underwritten sell-down to equity market investors and a selective share buy-back by Woodside. Shell's subsidiary, Shell Energy Holding Australia, or SEHAL, has mandated two investment banks to sell 78.27M shares in Woodside, through an underwritten sell-down at a price of A$41.35 per share. This part of the sale represents around 9.5% of the issued capital in Woodside, with the shares to be sold to a range of equity market investors. The sell-down is expected to complete on June 18. Under an agreement with SEHAL, Woodside will also buy-back 78.27M of its shares from SEHAL at a price of $34.24 per share. The buy-back price per share has been split into a dividend component of $26.29 per share and a capital component of $7.95 per share, as agreed with the Australian Taxation Office in a private ruling. SEHAL will receive franking credits on the dividend component with the effect that no further tax is payable by SEHAL on the dividend component. Completion of the buy-back will be subject to limited conditions, including consent under a number of Woodside's facility agreements, an independent expert opinion and Woodside shareholder approval. Completion of the buy-back is expected in early August.
News For A;WOPEY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
07:23 EDTAAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 5, 2015
05:29 EDTADako announces FDA approval of new companion diagnostic assay
Subscribe for More Information
October 2, 2015
15:57 EDTALabCorp to offer PD-L1 companion diagnostic
Subscribe for More Information
15:43 EDTAQuest Diagnostics introduces Dako's PD-L1 companion diagnostic for KEYTRUDA
Subscribe for More Information
15:25 EDTAAgilent's Dako confirms FDA approval of NSCLC diagnostic
Dako, an Agilent Technologies (A) company and a worldwide provider of cancer diagnostics, announced the FDA approval of a new companion diagnostic assay that can reveal whether a patient with advanced non-small cell lung cancer, or NSCLC, is likely to respond to a new form of treatment. The approval of PD-L1 IHC 22C3 pharmDx strengthens Dako's portfolio of companion diagnostics and the company's leadership position in developing and commercializing companion diagnostic products. Dako developed PD-L1 IHC 22C3 pharmDx in partnership with Merck (MRK), maker of the anti-PD-1 therapy Keytruda. The FDA approved PD-L1 IHC 22C3 pharmDx for use in the United States. Dako hopes to gain regulatory approval for the new diagnostic in Canada, Europe and other jurisdictions next year.
September 24, 2015
17:04 EDTAMerck, Pfizer to collaborate with Agilent's Dako on Avelumab diagnostic
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use